Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs.

Study Objectives: To test safety and tolerability of long-term moxifloxacin in resistant tuberculosis (TB) patients and patients with intolerance to first line anti-TB drugs.

Design: Clinical evaluation of adverse events (AEs) during prolonged moxifloxacin treatment.

Setting: TB Unit of the Regional TB Reference Center, Villa Marelli Institute, Niguarda Ca'Granda Hospital, Milan, Italy

Patients And Interventions: Patients treated with moxifloxacin, 400 mg orally once daily for TB in the Villa Marelli Institute from January 2001 to December 2003 were enrolled.